BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fragkos KC. Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea. Clin Exp Gastroenterol 2017;10:229-40. [PMID: 28989282 DOI: 10.2147/CEG.S123621] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Pakalapati S, Rumalla CS, Gudapati AR, Korupolu RB, Gajbhiye SB, Kaliyaperumal M. A novel RP-HPLC method development and validation for determination and estimation of eluxadoline drug with its impurities. SN Appl Sci 2020;2. [DOI: 10.1007/s42452-020-2834-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Rexwinkel R, Vlieger AM, Saps M, Tabbers MM, Benninga MA. A therapeutic guide on pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified. Eur J Pediatr 2022. [PMID: 35460383 DOI: 10.1007/s00431-022-04459-y] [Reference Citation Analysis]
3 Fragkos KC, Keetarut K, Cox A, Eady J, Emmanuel AV, Zarate-Lopez N. Joint Hypermobility Syndrome Affects Response to a Low Fermentable Oligosaccharide, Disaccharide, Monosaccharide and Polyol Diet in Irritable Bowel Syndrome Patients: A Retrospective Study. Gastroenterology Res 2019;12:27-36. [PMID: 30834032 DOI: 10.14740/gr1133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yerra S, Sharma H, B S, K MN, B VR. A novel stability-indicating HPLC method for the determination of enantiomeric purity of eluxadoline drug: Amylose tris(3,5-dichlorophenyl carbamate) stationary phase. Biomed Chromatogr 2021;:e5260. [PMID: 34623691 DOI: 10.1002/bmc.5260] [Reference Citation Analysis]
5 Lacy BE, Harris LA, Chang L, Lucak S, Gutman C, Dove LS, Covington PS, Lembo A. Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. Therap Adv Gastroenterol 2019;12:1756284819841290. [PMID: 31019552 DOI: 10.1177/1756284819841290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
6 Fleming MA 2nd, Ehsan L, Moore SR, Levin DE. The Enteric Nervous System and Its Emerging Role as a Therapeutic Target. Gastroenterol Res Pract 2020;2020:8024171. [PMID: 32963521 DOI: 10.1155/2020/8024171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]